# Atrial Fibrillation: Rate vs. Rhythm Control

## Classification and Epidemiology

### AF Classification

Atrial fibrillation is classified by temporal pattern and management strategy. Paroxysmal AF is self-terminating, typically within 48 hours though it may persist up to 7 days. Persistent AF is sustained beyond 7 days or requires cardioversion for termination. Long-standing persistent AF has been continuous for more than 12 months in a patient for whom a rhythm control strategy is still being pursued. Permanent AF represents the acceptance that rhythm control has been abandoned and rate control alone will be employed. First-diagnosed AF refers to any first-detected episode regardless of duration or symptoms.

### Epidemiology

Atrial fibrillation is the most common sustained arrhythmia, with an overall prevalence of 1 to 2% that increases to approximately 10% in those over age 80. The lifetime risk is 1 in 3 for individuals of European descent and 1 in 5 for those of African descent. The most common modifiable risk factor is hypertension, with other associated conditions including heart failure, valvular disease, obesity, obstructive sleep apnea, thyroid disease, alcohol use, COPD, chronic kidney disease, and diabetes. AF confers a five-fold increase in stroke risk, a two-fold increase in mortality, and a three-fold increase in heart failure risk.

### Pathophysiology

The triggering mechanism for AF involves ectopic foci that arise predominantly from muscular sleeves extending into the pulmonary veins. Autonomic triggers include vagal mechanisms producing nocturnal or postprandial onset and adrenergic mechanisms producing exercise-induced onset. The substrate for AF maintenance includes atrial fibrosis, electrical remodeling with shortened atrial refractory period, structural remodeling with left atrial dilation, and inflammation. The concept that "AF begets AF" reflects the electrical remodeling process by which sustained AF progressively shortens the refractory period, promoting maintenance and making termination increasingly difficult.

## Stroke Risk Assessment and Anticoagulation

### CHA2DS2-VASc Score

The CHA2DS2-VASc score assigns points for congestive heart failure or LV dysfunction (1), hypertension (1), age 75 or older (2), diabetes mellitus (1), stroke, TIA, or thromboembolism history (2), vascular disease including prior MI, peripheral arterial disease, or aortic plaque (1), age 65 to 74 (1), and female sex category (1). A score of 0 in males or 1 in females warrants no anticoagulation. A score of 1 in males supports considering anticoagulation as a Class IIa recommendation. A score of 2 or greater in males or 3 or greater in females constitutes a Class I indication for anticoagulation. Female sex alone does not warrant anticoagulation and only adds risk when other factors are present.

### Anticoagulation Options

Direct oral anticoagulants are preferred over warfarin for non-valvular AF. Apixaban at 5 mg twice daily, studied in the ARISTOTLE trial, demonstrated superiority to warfarin for both stroke prevention and reduced bleeding, with dose reduction to 2.5 mg twice daily when two or more of the following are present: age 80 or older, weight 60 kg or less, or creatinine 1.5 or greater. Rivaroxaban at 20 mg daily with an evening meal, studied in ROCKET-AF, was non-inferior to warfarin, with dose reduction to 15 mg for creatinine clearance of 15 to 50. Dabigatran at 150 mg twice daily, studied in RE-LY, was superior to warfarin for stroke prevention. Edoxaban at 60 mg daily, studied in ENGAGE AF-TIMI 48, was non-inferior to warfarin, with dose reduction to 30 mg for creatinine clearance of 15 to 50, weight 60 kg or less, or concomitant strong P-glycoprotein inhibitors. Warfarin remains indicated for moderate-to-severe mitral stenosis and mechanical heart valves, with a target INR of 2.0 to 3.0 and a time in therapeutic range goal exceeding 70%. DOAC contraindications include mechanical heart valves, moderate-to-severe rheumatic mitral stenosis, severe CKD with creatinine clearance below 15 to 25 depending on the agent, and pregnancy.

| DOAC | Landmark Trial | Dose | Dose Reduction Criteria | Key Result vs Warfarin |
|---|---|---|---|---|
| Apixaban | ARISTOTLE | 5 mg BID | 2.5 mg BID if >= 2 of: age >= 80, weight <= 60 kg, Cr >= 1.5 | Superior (stroke + bleeding) |
| Rivaroxaban | ROCKET-AF | 20 mg daily (with evening meal) | 15 mg daily if CrCl 15-50 | Non-inferior |
| Dabigatran | RE-LY | 150 mg BID | 75 mg BID if CrCl 15-30 | Superior (stroke prevention) |
| Edoxaban | ENGAGE AF-TIMI 48 | 60 mg daily | 30 mg daily if CrCl 15-50, weight <= 60 kg, or strong P-gp inhibitor | Non-inferior |

### Bleeding Risk Assessment

The HAS-BLED score incorporates hypertension, abnormal renal or liver function, stroke history, bleeding history, labile INR, elderly status over 65, and drugs or alcohol use, with a score of 3 or greater indicating high bleeding risk. Critically, a high HAS-BLED score should prompt management of modifiable bleeding risk factors rather than withholding anticoagulation, as the net clinical benefit favors anticoagulation in most patients with a CHA2DS2-VASc score of 2 or greater. Modifiable risk factors include uncontrolled hypertension, labile INR which may prompt switching to a DOAC, concomitant antiplatelets or NSAIDs, and excess alcohol.

### Left Atrial Appendage Occlusion

The WATCHMAN device, studied in the PROTECT AF and PREVAIL trials, demonstrated non-inferiority to warfarin for stroke prevention with higher procedural complications but lower long-term bleeding. Indications include patients with AF and contraindications to long-term anticoagulation such as prior life-threatening hemorrhage, recurrent gastrointestinal bleeding, or intracranial hemorrhage. Additional devices include the Lariat, Amulet, and surgical LAA ligation, which in the LAAOS III trial reduced stroke in patients undergoing cardiac surgery. Post-device antithrombotic therapy typically involves anticoagulation for 45 days followed by DAPT for 6 months, then aspirin lifelong, with TEE at 45 days to confirm device seal.

<image>
A clinical decision algorithm for anticoagulation in atrial fibrillation. Start with "Atrial Fibrillation Diagnosed" at top. First decision: "Valvular AF? (Moderate-severe mitral stenosis or mechanical valve)" → if yes: "Warfarin (DOACs contraindicated)." If no (non-valvular AF): "Calculate CHA2DS2-VASc Score" with the scoring system shown in a side table. Three outcomes: Score 0 (male) or 1 (female only): green box "No anticoagulation." Score 1 (male): yellow box "Consider anticoagulation (Class IIa)." Score >= 2 (male) or >= 3 (female): red box "Anticoagulation recommended (Class I)." Below the recommendation: "DOAC preferred over warfarin" with four options listed: apixaban 5mg BID, rivaroxaban 20mg daily, dabigatran 150mg BID, edoxaban 60mg daily, each with dose reduction criteria in small text. Side panel: "If anticoagulation contraindicated → LAA occlusion (WATCHMAN)." Bottom: "Assess bleeding risk (HAS-BLED) → modify reversible risk factors; high score does NOT preclude anticoagulation." Use traffic light colors: green for no AC, yellow for consider, red for strongly recommended.
</image>

## Rate Control

### Targets

The RACE II trial established that lenient rate control targeting a resting heart rate below 110 bpm was non-inferior to strict rate control targeting below 80 bpm for composite cardiovascular outcomes. A lenient target below 110 bpm is therefore reasonable for most patients, with strict control reserved for those with persistent symptoms despite lenient control or when tachycardia-mediated cardiomyopathy is suspected. Rate should be assessed during activity, not solely at rest, with 24-hour Holter monitoring useful to confirm adequate rate control.

### Pharmacotherapy

Beta-blockers including metoprolol, atenolol, and bisoprolol are first-line agents for most patients, providing good rate control during exercise, though they should be avoided in decompensated heart failure. Non-dihydropyridine calcium channel blockers, specifically diltiazem and verapamil, offer effective rate control but must be avoided in HFrEF due to negative inotropy and in WPW with preexcited AF. Digoxin controls resting but not exercise heart rate, has a narrow therapeutic window with target levels of 0.5 to 0.9 ng/mL, is useful as an add-on to beta-blockers or CCBs, must be used cautiously in renal failure, and has been associated with increased mortality in some observational studies in a dose-dependent fashion. Amiodarone provides modest rate control through AV nodal slowing but is reserved for situations where other agents fail or are contraindicated, given its significant long-term toxicity. Combination therapy with a beta-blocker plus digoxin, or a CCB plus digoxin, is common, but the combination of a beta-blocker with a non-dihydropyridine CCB should be avoided due to the risk of severe bradycardia and AV block.

### AV Node Ablation + Permanent Pacemaker

The "ablate and pace" strategy provides a permanent solution for refractory rate control when pharmacologic rate control fails despite multiple agents, persistent symptoms from rapid ventricular rate persist, or tachycardia-mediated cardiomyopathy develops. This approach requires a permanent pacemaker, preferably CRT if ejection fraction is reduced to avoid right ventricular pacing-induced cardiomyopathy. This is an irreversible procedure that renders the patient pacemaker-dependent, and anticoagulation must be continued because AF persists.

## Rhythm Control

### EAST-AFNET 4 Trial -- Paradigm Shift

The EAST-AFNET 4 trial demonstrated that early rhythm control, initiated within 1 year of AF diagnosis, reduced the composite of cardiovascular death, stroke, and heart failure hospitalization by 21% compared with rate control. The benefit was greatest with earlier initiation, within months of diagnosis. This trial shifted clinical practice toward favoring rhythm control for early AF diagnosed within 1 year, especially when accompanied by risk factors for stroke or heart failure.

### Electrical Cardioversion

Synchronized direct current shock is performed using anterior-posterior pad placement, preferred over anterior-lateral, with biphasic waveform energy of 120 to 200 joules for AF and 50 to 100 joules for atrial flutter. Anticoagulation management depends on the duration of AF: for AF lasting less than 48 hours, cardioversion may proceed without prolonged anticoagulation, though anticoagulation should be started promptly in high stroke risk patients, with post-cardioversion anticoagulation determined by CHA2DS2-VASc score. For AF of 48 hours or more or unknown duration, 3 weeks of therapeutic anticoagulation before cardioversion plus 4 weeks after is required, or alternatively TEE may be performed to exclude LAA thrombus, allowing immediate cardioversion if no thrombus is identified followed by 4 weeks of post-cardioversion anticoagulation. Long-term anticoagulation decisions are based on CHA2DS2-VASc score, not on maintenance of sinus rhythm, as stroke risk persists even after successful cardioversion. The success rate for initial cardioversion is approximately 90%, but maintenance of sinus rhythm at 1 year without antiarrhythmic drugs is only 20 to 30%.

### Antiarrhythmic Drug Therapy

#### Flecainide

Flecainide is a Class IC sodium channel blocker that is highly effective for paroxysmal AF at a dose of 100 to 200 mg twice daily. It must be combined with an AV nodal blocker such as a beta-blocker or CCB to prevent 1:1 atrial flutter conduction. It is absolutely contraindicated in structural heart disease including coronary artery disease, heart failure, and left ventricular hypertrophy, based on the CAST trial which demonstrated increased mortality with flecainide and encainide in post-MI patients. The "pill-in-pocket" approach allows patient-directed single-dose administration of 200 to 300 mg at the onset of paroxysmal AF for self-termination, with the first use supervised in a monitored setting.

#### Propafenone

Propafenone is a Class IC agent similar to flecainide, dosed at 150 to 300 mg three times daily or 225 to 425 mg twice daily in sustained-release formulation. It shares the same contraindications as flecainide but has mild beta-blocking properties. A pill-in-pocket dose of 450 to 600 mg as a single dose is available.

#### Sotalol

Sotalol combines Class III potassium channel blocking with non-selective beta-blocking properties at doses of 80 to 160 mg twice daily. QT prolongation carries a risk of torsades de pointes at 2 to 4%, requiring inpatient initiation with QTc monitoring for the first 3 days. The drug is renally cleared and requires dose adjustment, with avoidance if creatinine clearance falls below 40. Sotalol is safe in coronary artery disease but should be used cautiously in heart failure.

#### Dofetilide

Dofetilide is a pure Class III agent dosed at 125 to 500 mcg twice daily that requires mandatory inpatient initiation for a minimum of 3 days with QTc and renal function monitoring. Dosing is based on creatinine clearance: 500 mcg twice daily if clearance exceeds 60, 250 mcg if 40 to 60, 125 mcg if 20 to 40, and contraindicated if below 20. QTc must be monitored 2 to 3 hours after each dose and the drug held if QTc exceeds 500 ms or increases more than 15% from baseline. Drug interactions are critical, with metformin, trimethoprim, cimetidine, and ketoconazole increasing dofetilide levels via renal cation transport and requiring avoidance. Dofetilide is safe in heart failure, as the DIAMOND-CHF trial showed neutral effects on mortality.

#### Amiodarone

Amiodarone possesses multi-class antiarrhythmic properties (Classes I, II, III, and IV) and is the most effective AAD for maintaining sinus rhythm at approximately 65 to 70% at 1 year. Its toxicity profile is extensive, including thyroid dysfunction both hypo and hyper at 10 to 15%, pulmonary fibrosis at 1 to 5%, hepatotoxicity with elevated liver function tests in 15 to 30%, corneal microdeposits in more than 90%, skin photosensitivity and blue discoloration, peripheral neuropathy, and optic neuropathy. Monitoring requires thyroid function tests, liver function tests, pulmonary function tests, chest radiography, and eye examinations at baseline and every 6 to 12 months. Loading doses are typically 400 mg three times daily for one week, 400 mg twice daily for one week, then 200 mg daily for maintenance. The drug has a long half-life of 40 to 55 days with effects persisting weeks after discontinuation. Amiodarone is unique among antiarrhythmic drugs in being safe in heart failure and coronary artery disease, with minimal proarrhythmic risk and torsades de pointes rates below 0.5%. It should be used as first-line only in HFrEF or significant structural heart disease where other agents are contraindicated.

#### Dronedarone

| AAD | Class | Dose | Safe in CAD | Safe in HFrEF | Key Risk/Monitoring | Contraindications |
|---|---|---|---|---|---|---|
| Flecainide | IC | 100-200 mg BID | No | No | 1:1 flutter; must add AV nodal blocker | Structural heart disease (CAST) |
| Propafenone | IC | 150-300 mg TID or SR 225-425 mg BID | No | No | Mild beta-blocking | Structural heart disease |
| Sotalol | III + beta | 80-160 mg BID | Yes | Caution | QT prolongation, TdP (2-4%); inpatient initiation x 3 days | CrCl < 40; QTc > 500 ms |
| Dofetilide | III | 125-500 mcg BID | Yes | Yes | Mandatory inpatient initiation x 3 days; QTc monitoring; renal dosing | CrCl < 20; many drug interactions |
| Amiodarone | I/II/III/IV | 200 mg daily (maintenance) | Yes | Yes | Thyroid, pulmonary, hepatic, ocular toxicity; monitor q6-12mo | Few cardiac contraindications |
| Dronedarone | Multi-class | 400 mg BID | Yes | No | Lower toxicity than amiodarone | HFrEF (ANDROMEDA); permanent AF (PALLAS) |

Dronedarone is an amiodarone analog without the iodine moiety, dosed at 400 mg twice daily. The ATHENA trial demonstrated reduced cardiovascular hospitalization and death compared with placebo in moderate-risk AF. It is contraindicated in HFrEF or recent decompensated heart failure based on the ANDROMEDA trial which showed increased mortality, and in permanent AF based on the PALLAS trial which showed increased stroke and cardiovascular death. Its use is limited to paroxysmal or persistent AF without significant heart failure or structural heart disease.

### Catheter Ablation for AF

#### Mechanism and Technique

Pulmonary vein isolation, the electrical disconnection of pulmonary vein muscle sleeves from the left atrium, is the cornerstone of all AF ablation strategies. Techniques include radiofrequency point-by-point ablation, cryoballoon ablation, and pulsed-field ablation, which is tissue-selective and spares the esophagus and phrenic nerve. Additional substrate modification approaches including posterior wall isolation, linear ablation of the mitral isthmus and roof line, complex fractionated atrial electrogram ablation, and Marshall vein ethanol infusion have evolving roles. The CASTLE-AF trial demonstrated that catheter ablation reduced death plus heart failure hospitalization by 38% compared with medical therapy in HFrEF patients with AF, establishing ablation as first-line rhythm control in this population.

#### Efficacy

For paroxysmal AF, single-procedure freedom from AF at 1 year is approximately 70 to 80%, improving to 85 to 90% after redo procedures. For persistent AF, single-procedure success is approximately 50 to 60%, often requiring repeat procedures and additional substrate modification. Factors favoring success include paroxysmal AF, smaller left atrium below 50 to 55 mm, shorter AF duration, younger age, and absence of significant structural heart disease. Factors associated with recurrence include persistent or long-standing persistent AF, dilated left atrium, obesity, and untreated obstructive sleep apnea.

#### Complications

Pulmonary vein stenosis occurs in less than 1% with current techniques when ablation is performed outside the PV ostium. Esophageal injury and atrioesophageal fistula are rare at 0.01 to 0.05% but potentially fatal, and pulsed-field ablation may reduce this risk. Pericardial effusion and tamponade occur in 1 to 2% and are treated with pericardiocentesis. Stroke and TIA occur in less than 1% with appropriate anticoagulation. Phrenic nerve palsy occurs in 1 to 3% with cryoballoon use due to right pulmonary vein proximity and is usually transient. Vascular access complications occur in 1 to 3%.

<image>
A posterior view of the left atrium showing pulmonary vein anatomy and ablation lesion sets for atrial fibrillation. The LA should be shown from the posterior aspect with the four pulmonary veins (right superior PV, right inferior PV, left superior PV, left inferior PV) entering the LA at the four corners. Circumferential ablation lesion sets (shown as red dotted circles) should surround each pair of ipsilateral PVs (wide antral circles). Label additional lesion sets in lighter red: roof line (connecting superior aspects of the two PV circles), mitral isthmus line (from left inferior PV to mitral annulus), and posterior wall box isolation. The esophagus should be shown in yellow running behind the posterior LA wall (close to the left inferior PV), labeled with a warning symbol indicating risk zone for esophageal injury. The coronary sinus should be visible inferiorly. The Marshall vein should be labeled entering near the left PVs. Include annotations showing: (1) RF point-by-point lesions as individual dots, (2) Cryoballoon lesion as a smooth circle, (3) PFA lesion set as a different pattern. Use anatomic coloring with the LA wall in pink, PVs in blue/purple, ablation lesions in red.
</image>

## Specific Clinical Scenarios

### AF with HFrEF

Rhythm control is preferred in this population, supported by CASTLE-AF for ablation and EAST-AFNET 4 for early rhythm control. Rate control agents should be limited to heart failure-approved beta-blockers including carvedilol, metoprolol succinate, and bisoprolol, with digoxin as an add-on, and non-dihydropyridine CCBs avoided due to negative inotropy. Amiodarone is the first-line antiarrhythmic drug in HFrEF, with dofetilide as an alternative. Catheter ablation should be considered as first-line rhythm control based on evidence from CASTLE-AF, AMICA, and RAFT-AF.

### AF with WPW (Preexcited AF)

This presents as a wide-complex irregularly irregular tachycardia with rapid ventricular response, often exceeding 200 bpm. AV nodal blockers are absolutely contraindicated, including digoxin, verapamil, diltiazem, and adenosine, as they may enhance accessory pathway conduction and precipitate ventricular fibrillation. Treatment consists of IV procainamide, which is preferred, or ibutilide, with electrical cardioversion for hemodynamic instability. Definitive therapy is accessory pathway ablation.

### Postoperative AF

Postoperative AF occurs in 25 to 40% of cardiac surgery patients, with peak incidence on days 2 to 3. Prevention relies on perioperative beta-blockers, particularly continuation of home beta-blocker therapy, with amiodarone prophylaxis in high-risk patients. The arrhythmia is usually self-limiting. Anticoagulation is indicated if AF persists beyond 48 hours or the CHA2DS2-VASc score is elevated, with continuation for at least 4 weeks post-cardioversion.

## Key Clinical Pearls

- Anticoagulation decisions are based on CHA2DS2-VASc, NOT on AF type or burden -- a patient with paroxysmal AF and CHA2DS2-VASc of 4 has the same stroke risk as persistent AF with the same score
- The EAST-AFNET 4 trial supports EARLY rhythm control (within 1 year of diagnosis) -- waiting years to pursue rhythm control loses the window of greatest benefit
- Flecainide and propafenone are effective for paroxysmal AF but must NEVER be used in patients with structural heart disease (CAD, HF, significant LVH) -- always screen with echo and exercise test before prescribing
- Dofetilide REQUIRES inpatient initiation and is one of the most drug-interaction-sensitive medications in cardiology -- the physician must personally verify CrCl and concomitant medications; incorrect dosing can cause fatal TdP
- Catheter ablation for AF in HFrEF has the strongest evidence of any rhythm control strategy to reduce mortality and HF hospitalization -- CASTLE-AF should prompt ablation referral in all suitable HFrEF patients with AF
- Successful cardioversion/ablation does NOT eliminate the need for anticoagulation if CHA2DS2-VASc indicates treatment -- silent AF recurrence is common, and stroke risk persists

## References

- Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149:e1-e156.
- Kirchhof P, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation (EAST-AFNET 4). NEJM. 2020;383:1305-1316.
- Marrouche NF, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure (CASTLE-AF). NEJM. 2018;378:417-427.
- Van Gelder IC, et al. Lenient versus Strict Rate Control in Patients with Atrial Fibrillation (RACE II). NEJM. 2010;362:1363-1373.
- Granger CB, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation (ARISTOTLE). NJM. 2011;365:981-992.